Markets:

Overview

News

Currencies

International

Treasuries

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED

Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Wayfair To Rally Over 32%? Here Are 10 Other Analyst Forecasts For Monday ↗

August 07, 2023

Needham raised the price target for MACOM Technology Solutions Holdings, Inc. (NASDAQ: MTSI) from $65 to $84. Needham analyst Quinn Bolton maintained a Buy rating. MACOM Technology shares rose 0.1% to...

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

July 31, 2023

Via Benzinga

What 10 Analyst Ratings Have To Say About Sage Therapeutics ↗

July 27, 2023

Via Benzinga

Why Sage Therapeutics Stock Is Tumbling Today ↗

July 26, 2023

A partner's perceived lack of enthusiasm for an upcoming regulatory decision is spooking investors today.

Via The Motley Fool

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

July 26, 2023

Via Benzinga

Expert Ratings for Sage Therapeutics ↗

May 09, 2023

Via Benzinga

Sage Therapeutics's Earnings Outlook ↗

May 01, 2023

Via Benzinga

What 5 Analyst Ratings Have To Say About Sage Therapeutics ↗

March 09, 2023

Via Benzinga

Earnings Scheduled For February 16, 2023 ↗

February 16, 2023

Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗

July 27, 2023

Via Benzinga

Analyst Creates Bullish Pitch For Sage Therapeutics Around Greater Enthusiasm For Its Depression Drug, Zuranolone ↗

March 13, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 13, 2023 ↗

March 13, 2023

Via Benzinga

Why Universal Health Services Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 26, 2023

Gainers Silicon Motion Technology Corporation (NASDAQ: SIMO) shares climbed 78.9% to $93.40 following a report suggesting China approval of the company's Maxlinear merger.

Via Benzinga

Illumina, Seagen And Other Big Stocks Moving Higher On Monday ↗

March 13, 2023

U.S. stocks traded slightly lower, with the Nasdaq Composite dropping around 0.2% on Monday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Expert Ratings for Sage Therapeutics ↗

December 06, 2022

Via Benzinga

Sage Therapeutics's Return On Capital Employed Insights ↗

December 05, 2022

Via Benzinga

Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate ↗

October 17, 2022

Via Benzinga

Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

March 13, 2023

Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash.

Via Benzinga

Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive' ↗

February 06, 2023

Via Benzinga

Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗

September 09, 2022

On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91.

Via Investor's Business Daily

Sage Therapeutics: Q2 Earnings Insights ↗

August 02, 2022

Sage Therapeutics (NASDAQ:SAGE) reported its Q2 earnings results on Tuesday, August 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Via Benzinga

Where Sage Therapeutics Stands With Analysts ↗

July 11, 2022

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Via Benzinga

8 Analysts Have This to Say About Sage Therapeutics ↗

May 24, 2022

Analysts have provided the following ratings for Sage Therapeutics (NASDAQ:SAGE) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help ↗

August 11, 2022

Today's depression drugs don't fit many patients' needs. Biotech companies may change that.

Via Investor's Business Daily

Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study ↗

August 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Sage Therapeutics And Biogen Tackle Depression — And Their Stocks Do The Same ↗

June 01, 2022

Sage and Biogen say their MDD drug met every goal in a study of postpartum women.

Via Investor's Business Daily

Analyst Ratings for Sage Therapeutics ↗

May 04, 2022

Over the past 3 months, 7 analysts have published their opinion on Sage Therapeutics (NASDAQ:SAGE) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding...

Via Benzinga

The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs ↗

May 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Earnings Scheduled For August 2, 2022 ↗

August 02, 2022

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

Headline News about Sage Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today